Dlgap5-KO Mouse
一般名
Dlgap5-KO
製品ID
S-KO-15726
背景情報
C57BL/6JCya
系統ID
KOCMP-218977-Dlgap5-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Dlgap5-KO Mouse（カタログ番号S-KO-15726）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Dlgap5-KO
系統ID
KOCMP-218977-Dlgap5-B6J-VA
遺伝子名
製品ID
S-KO-15726
遺伝子別名
Dlg7, Hurp, Dap-5, mKIAA0008
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 14
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000043296
NCBIトランスクリプトID
NM_144553
ターゲット領域
Exon 3~15
有効領域の大きさ
~20.8 kb
遺伝子研究の概要
Dlgap5, also known as DLG7, encodes a microtubule-associated protein DLG7 which is crucial during spindle assembly. Spindle assembly regulation is vital for maintaining genomic stability, thus Dlgap5 is of great biological importance in cell division processes [8].
In multiple cancer types, Dlgap5 shows oncogenic properties. In lung adenocarcinoma, its high expression is associated with poor prognosis, and it promotes cancer growth by upregulating PLK1 [1]. In bladder cancer, it triggers cell proliferation and metastasis by stabilizing E2F1 via USP11, and also enhances chemoresistance by regulating glycolysis through MYC stabilization [2,3]. In prostate adenocarcinoma, it promotes neuroendocrine differentiation by upregulating E2F1 [4]. In endometrial cancer, knockdown of Dlgap5 inactivates the Wnt/β-catenin signal to repress cell malignant activities [5]. In gallbladder cancer, it promotes migration and tumor-associated macrophage M2 polarization by activating cAMP [6]. In breast cancer, it regulates cell proliferation, migration, invasion, and cell cycle via the JAK2/STAT3 signaling axis [7]. In colorectal cancer, its downregulation reduces invasion and migration potential, and overexpression is linked to poor survival in non-metastatic patients [8]. In ovarian cancer, knockdown of Dlgap5 suppresses cell proliferation, induces G2/M phase arrest and apoptosis [9].
In conclusion, Dlgap5 plays a significant role in cell division-related processes and is closely associated with the development and progression of various cancers. Functional studies, especially those using knockdown models in different cancer cell lines, have revealed its oncogenic functions in promoting cancer cell proliferation, migration, invasion, and in some cases, regulating cancer-related signaling pathways. This understanding of Dlgap5's role in cancer provides potential therapeutic targets for treating these malignancies.
References:
1. Chen, Maojian, Zhang, Shaoping, Wang, Fan, Jiang, Wei, Zhang, Li. 2024. DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target. In Journal of translational medicine, 22, 209. doi:10.1186/s12967-024-04910-8. https://pubmed.ncbi.nlm.nih.gov/38414025/
2. Zhou, Fenfang, Deng, Zhao, Shen, Dexin, Ju, Lingao, Wang, Xinghuan. 2024. DLGAP5 triggers proliferation and metastasis of bladder cancer by stabilizing E2F1 via USP11. In Oncogene, 43, 594-607. doi:10.1038/s41388-023-02932-y. https://pubmed.ncbi.nlm.nih.gov/38182895/
3. Deng, Zhao, Zhou, Fenfang, Li, Mingxing, Xiao, Yu, Wang, Xinghuan. 2025. DLGAP5 enhances bladder cancer chemoresistance by regulating glycolysis through MYC stabilization. In Theranostics, 15, 2375-2392. doi:10.7150/thno.102730. https://pubmed.ncbi.nlm.nih.gov/39990228/
4. Liang, Linghui, Shen, Zhiyi, Zhang, Kaiyu, Zhao, Ruizhe, Feng, Ninghan. 2025. DLGAP5 upregulates E2F1 to promote prostate adenocarcinoma neuroendocrine differentiation. In Life sciences, 365, 123442. doi:10.1016/j.lfs.2025.123442. https://pubmed.ncbi.nlm.nih.gov/39923838/
5. Chen, Ruipu, Liu, Jing, Hu, Jun, Liu, Yanhua, Pan, Weiwei. 2022. DLGAP5 knockdown inactivates the Wnt/β-catenin signal to repress endometrial cancer cell malignant activities. In Environmental toxicology, 38, 685-693. doi:10.1002/tox.23720. https://pubmed.ncbi.nlm.nih.gov/36454672/
6. Huang, Jie, Zheng, Mengyao, Li, Yan, Xu, Dingwei, Tian, Daguang. 2023. DLGAP5 promotes gallbladder cancer migration and tumor-associated macrophage M2 polarization by activating cAMP. In Cancer immunology, immunotherapy : CII, 72, 3203-3216. doi:10.1007/s00262-023-03484-6. https://pubmed.ncbi.nlm.nih.gov/37421434/
7. Li, Yujie, Wei, Jie, Sun, Yao, Zhang, Huan, Jin, Tianbo. 2023. DLGAP5 Regulates the Proliferation, Migration, Invasion, and Cell Cycle of Breast Cancer Cells via the JAK2/STAT3 Signaling Axis. In International journal of molecular sciences, 24, . doi:10.3390/ijms242115819. https://pubmed.ncbi.nlm.nih.gov/37958803/
8. Branchi, Vittorio, García, Sebastián A, Radhakrishnan, Praveen, Reißfelder, Christoph, Schölch, Sebastian. 2019. Prognostic value of DLGAP5 in colorectal cancer. In International journal of colorectal disease, 34, 1455-1465. doi:10.1007/s00384-019-03339-6. https://pubmed.ncbi.nlm.nih.gov/31286215/
9. Zhang, Huijun, Liu, Yuan, Tang, Shengchun, Zhang, Jing, Liu, Bo. 2021. Knockdown of DLGAP5 suppresses cell proliferation, induces G2/M phase arrest and apoptosis in ovarian cancer. In Experimental and therapeutic medicine, 22, 1245. doi:10.3892/etm.2021.10680. https://pubmed.ncbi.nlm.nih.gov/34539841/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。